Cargando…
The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new virus discovered in December 2019 that causes coronavirus disease 19 (COVID-19) and various vaccinations have been developed. The extent to which COVID-19 infections and/or COVID-19 vaccinations alter antiphospholipid antibodies (...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051980/ https://www.ncbi.nlm.nih.gov/pubmed/36982716 http://dx.doi.org/10.3390/ijms24065644 |
_version_ | 1785015022155464704 |
---|---|
author | Ott, Olivia Herrmann, Eva Schulz, Annabel Lindhoff-Last, Edelgard |
author_facet | Ott, Olivia Herrmann, Eva Schulz, Annabel Lindhoff-Last, Edelgard |
author_sort | Ott, Olivia |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new virus discovered in December 2019 that causes coronavirus disease 19 (COVID-19) and various vaccinations have been developed. The extent to which COVID-19 infections and/or COVID-19 vaccinations alter antiphospholipid antibodies (aPL) in patients with thromboembolic antiphospholipid syndrome (APS) remains unclear. Eighty-two patients with confirmed thromboembolic APS were included in this prospective non-interventional trial. Blood parameters including lupus anticoagulants, anticardiolipin IgG- and IgM-antibodies, and anti-ß2-glycoprotein I IgG- and IgM-antibodies were assessed prior to and after COVID-19 vaccination and/or COVID-19 infection. No increases in aPL in the total study population were detected. In fact, low but significant decreases were observed for anticardiolipin IgG- and anti-β2-glycoprotein I IgG-antibodies, while anticardiolipin IgM- and anti-b2-glycoprotein I IgM-antibodies slightly increased only in patients with COVID-19 infection and vaccination. Although the investigated patient group is known to have a high risk of recurrent thrombosis, only one arterial thrombotic event was diagnosed (1.2%, 1/82). This low recurrence rate was probably due to the high vaccination rates prior to infections and a high rate of effective anticoagulation. Our data show that COVID-19 infections and/or vaccinations do not deteriorate the clinical course of anticoagulated thromboembolic APS patients. |
format | Online Article Text |
id | pubmed-10051980 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100519802023-03-30 The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination Ott, Olivia Herrmann, Eva Schulz, Annabel Lindhoff-Last, Edelgard Int J Mol Sci Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new virus discovered in December 2019 that causes coronavirus disease 19 (COVID-19) and various vaccinations have been developed. The extent to which COVID-19 infections and/or COVID-19 vaccinations alter antiphospholipid antibodies (aPL) in patients with thromboembolic antiphospholipid syndrome (APS) remains unclear. Eighty-two patients with confirmed thromboembolic APS were included in this prospective non-interventional trial. Blood parameters including lupus anticoagulants, anticardiolipin IgG- and IgM-antibodies, and anti-ß2-glycoprotein I IgG- and IgM-antibodies were assessed prior to and after COVID-19 vaccination and/or COVID-19 infection. No increases in aPL in the total study population were detected. In fact, low but significant decreases were observed for anticardiolipin IgG- and anti-β2-glycoprotein I IgG-antibodies, while anticardiolipin IgM- and anti-b2-glycoprotein I IgM-antibodies slightly increased only in patients with COVID-19 infection and vaccination. Although the investigated patient group is known to have a high risk of recurrent thrombosis, only one arterial thrombotic event was diagnosed (1.2%, 1/82). This low recurrence rate was probably due to the high vaccination rates prior to infections and a high rate of effective anticoagulation. Our data show that COVID-19 infections and/or vaccinations do not deteriorate the clinical course of anticoagulated thromboembolic APS patients. MDPI 2023-03-15 /pmc/articles/PMC10051980/ /pubmed/36982716 http://dx.doi.org/10.3390/ijms24065644 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ott, Olivia Herrmann, Eva Schulz, Annabel Lindhoff-Last, Edelgard The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination |
title | The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination |
title_full | The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination |
title_fullStr | The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination |
title_full_unstemmed | The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination |
title_short | The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination |
title_sort | apsantico study: a prospective observational study to evaluate antiphospholipid antibody profiles in patients with thromboembolic antiphospholipid syndrome (aps) after covid-19 infection and/or vaccination |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051980/ https://www.ncbi.nlm.nih.gov/pubmed/36982716 http://dx.doi.org/10.3390/ijms24065644 |
work_keys_str_mv | AT ottolivia theapsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination AT herrmanneva theapsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination AT schulzannabel theapsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination AT lindhofflastedelgard theapsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination AT ottolivia apsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination AT herrmanneva apsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination AT schulzannabel apsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination AT lindhofflastedelgard apsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination |